Stock Analiz

Madrigal Pharmaceuticals, Inc. (MDGL) stock forecast and price target

Price $427.39 · data as of November 13, 2026

12-month price target

Average target$688.78
Upside / downside+61.2%
Analysts18
ConsensusStrong buy
Low $479.00Average $688.78High $962.00

Gold marker: average target · white marker: today’s price ($427.39)

Analyst ratings

Strong buy 3Buy 15Hold 1Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-2.00+84.3%$1.6B
Next fiscal year
ends December 31, 2027
$11.21+660.5%$2.2B
Next quarter
ends December 31, 2026
$1.92+174.7%$478M
Quarter after
ends March 31, 2027
$0.79+157.2%$459M

Consensus of the analysts covering Madrigal Pharmaceuticals, updated daily.

Our model vs. Wall Street

Analysts see 61.2% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Madrigal Pharmaceuticals’s intrinsic value about 84% below today’s market value, and it scores 1.0 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.

Frequently asked questions

What is the Madrigal Pharmaceuticals stock price target?

The average 12-month target from 18 analysts is $688.78, 61.2% above the current price of $427.39 Targets range from $479.00 to $962.00.

Is Madrigal Pharmaceuticals a buy according to analysts?

The consensus rating is “Strong buy” (3 strong buy, 15 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Madrigal Pharmaceuticals expected to earn?

Analysts expect EPS of $-2.00 for the fiscal year ending December 31, 2026 and $11.21 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.